ArticleBiomolecules2021
Beneficial Modulation of Lipid Mediator Biosynthesis in Innate Immune Cells by Antirheumatic
Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Metabolomics and Mechanistic Approaches Reveal the Synergistic and Attenuating of Rubus chingii Hu on Tripterygium Glycoside Tablets in the Treatment of Rheumatoid Arthritis.Chemistry & biodiversity · 2026Article
- Validated bioanalysis of oxylipins confirms specialized pro-resolving mediator formation in vitro and in vivo.Journal of lipid research · 2026Article
- Review
- Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Immunocyte lipid metabolic reprogramming: a novel pathway for targeted intervention in autoimmune diseases.Frontiers in immunology · 2025Review
- Targeting dysregulated intracellular immunometabolism within synovial microenvironment in rheumatoid arthritis with natural products.Frontiers in pharmacology · 2024Review
- Cannabidiol acts as molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators.Cell chemical biology · 2023Article
- Establishment and Characterization of Mild Atopic Dermatitis in the DNCB-Induced Mouse Model.International journal of molecular sciences · 2023Article
- A comprehensive review ofFrontiers in pharmacology · 2023Review
- Modulation of Inflammation-Related Lipid Mediator Pathways by Celastrol During Human Macrophage Polarization.Journal of inflammation research · 2022Article
- Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201.Journal of inflammation research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.